Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 30.52% is 18% below its 5-year average of 37.17%, near the low end of its 5-year range (21.26%–74.19%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.36% below its 12-month average of 41.44%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 30.52%.
DEBT TO ASSETS RATIO
30.52%
DEBT TO ASSETS RATIO AVG TTM
41.44%
DEBT TO ASSETS RATIO AVG 3Y
42.15%
DEBT TO ASSETS RATIO AVG 5Y
37.17%
DEBT TO ASSETS RATIO AVG 10Y
31.29%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-26.36%
CURRENT VS 3Y AVG
-27.61%
CURRENT VS 5Y AVG
-17.91%
CURRENT VS 10Y AVG
-2.46%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+33806.36%
vs the sector median at left
X4 Pharmaceuticals, Inc.
Market Cap
$261.27M
Debt to Assets Ratio
30.52%
TTM Avg
41.44%
3Y Avg
42.15%
5Y Avg
37.17%
Market Cap
$261.43M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
Debt to Assets Ratio
0.55%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.56M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.49M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.14M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.12M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.63M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.25M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $261.27M | 30.52% | 41.44% | 42.15% | 37.17% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 0.55% | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 0.03% | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 0.40% | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.01% | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.03% | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 0.00% | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 0.10% | N/A | N/A | N/A |
Debt/Assets
30.5%
Debt/Equity
0.50
Current Ratio
11.30
Interest Coverage
-9.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 30.52% |
| 2026-03-31 | 28.58% |
| 2025-12-31 | 26.61% |
| 2025-09-30 | 47.30% |
| 2025-06-30 | 74.19% |
| 2025-03-31 | 60.03% |
| 2024-12-31 | 53.32% |
| 2024-09-30 | 43.89% |
| 2024-06-30 | 37.14% |
| 2024-03-31 | 51.95% |
| 2023-12-31 | 39.58% |
| 2023-09-30 | 33.63% |
| 2023-06-30 | 21.26% |
| 2023-03-31 | 29.69% |
| 2022-12-31 | 24.69% |
| 2022-09-30 | 33.79% |
| 2022-06-30 | 47.36% |
| 2022-03-31 | 38.96% |
| 2021-12-31 | 33.95% |
| 2021-09-30 | 33.06% |
| 2021-06-30 | 28.15% |
| 2021-03-31 | 24.72% |
| 2020-12-31 | 31.29% |
| 2020-09-30 | 23.26% |
| 2020-06-30 | 19.49% |
| 2020-03-31 | 18.13% |
| 2019-12-31 | 14.26% |
| 2019-09-30 | 21.01% |
| 2019-06-30 | 21.82% |
| 2019-03-31 | 36.42% |
| 2018-12-31 | 98.87% |
| 2018-09-30 | 23.39% |
| 2018-06-30 | 19.56% |
| 2018-03-31 | 17.36% |
| 2017-12-31 | 15.06% |
| 2017-09-30 | 33.68% |
| 2017-06-30 | 32.12% |
| 2017-03-31 | 183.63% |
